73278 Federal Register / Vol. 79, No. 237 / Wednesday, December 10, 2014 / Notices 

owned or controlled by one of the 

following persons or group of persons: 

African American, American Indian, 

Alaska Native, Asian, Hispanic, Native 

Hawaiian, Pacific Islander, Asian 

Indian, and Hasidic Jew. MBDA 

provides management and technical 

assistance to large, medium, and small 

minority business enterprises through a 

network of business centers throughout 

the United States. 

Since 1983, every president has 

issued a Presidential Proclamation 

designating one week as National 

Minority Enterprise Development (MED) 

Week. MBDA recognizes the role that 

minority entrepreneurs play in building 

the Nation’s economy by honoring 

businesses that are making a significant 

contribution through the creation of 

jobs, products and services, in addition 

to supporting their local communities. 

The MED Week Awards Program is a 

key element of MED Week and 

celebrates the outstanding achievements 

of minority entrepreneurs. MBDA may 

make awards in the following 

categories: Minority Construction Firm 

of the Year, Minority Manufacturer of 

the Year, Minority Export Firm of the 

Year, Minority Energy Firm of the Year, 

Minority Health Products and Services 

Firm of the Year, Minority Technology 

Firm of the Year, Minority Marketing 

and Communication Firm of the Year, 

Minority Professional Services Firm of 

the Year and the MBDA Minority 

Business Enterprise of the Year award. 

In addition, MBDA may recognize 

trailblazers and champions through the 

Access to Capital Award, Advocate of 

the Year Award, Distinguished Supplier 

Diversity Award, Ronald H. Brown 

Leadership Award, and Abe Venable 

Legacy Award for Lifetime 

Achievement. All awards will be 

presented at a ceremony during 

National MED Week. Nominations for 

these awards are open to the public. 

MBDA must collect two types of 

information: (a) Information identifying 

the nominee and nominator, and (b) 

information explaining why the 

nominee should be given the award. 

The information will be used to 

determine those applicants best meeting 

the preannounced evaluation criterion. 

Use of a nomination form standardizes 

and limits the information collected as 

part of the nomination process. This 

makes the competition fair and eases the 

burden on applicants and reviewers. 

Participation in the MED Week Awards 

Program competition is voluntary and 

the awards are strictly honorary. 

II. Method of Collection 

The form may be submitted 

electronically or paper format. 

III. Data 

OMB Control Number: 0640–0025. 

Form Number(s): Not applicable. 

Type of Review: Regular submission. 

Affected Public: Businesses or other 

for profit organizations, not-for-profit 

institutions, State, Local, or Tribal 

government, and Federal government. 

Estimated Number of Respondents: 

100. 

Estimated Time per Response: 2 

hours. 

Estimated Total Annual Burden 

Hours: 200. 

Estimated Total Annual Cost to 

Public: $0. 

IV. Request for Comments 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden 

(including hours and cost) of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. 

Comments submitted in response to 

this notice will be summarized and/or 

included in the request for OMB 

approval of this information collection; 

they also will become a matter of public 

record. 

Dated: December 4, 2014. 

Glenna Mickelson, 

Management Analyst, Office of the Chief 

Information Officer. 

[FR Doc. 2014–28846 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–21–P 

DEPARTMENT OF COMMERCE 

National Oceanic and Atmospheric 

Administration 

Solicitation for Members of the NOAA 

Science Advisory Board 

AGENCY: National Oceanic and 

Atmospheric Administration (NOAA), 

Office of Oceanic and Atmospheric 

Research, Department of Commerce. 

ACTION: Notice of solicitation for 

members of the NOAA Science 

Advisory Board. 

SUMMARY: NOAA is soliciting 

nominations for members of the NOAA 

Science Advisory Board (SAB). The 

SAB is the only Federal Advisory 

Committee with the responsibility to 

advise the Under Secretary of 

Commerce for Oceans and Atmosphere 

and NOAA Administrator on long- and 

short-range strategies for research, 

education, and application of science to 

resource management and 

environmental assessment and 

prediction. The SAB consists of 15 

members reflecting the full breadth of 

NOAA’s areas of responsibility and 

assists NOAA in maintaining a complete 

and accurate understanding of scientific 

issues critical to the agency’s missions. 

Points of View: The Board will consist 

of approximately fifteen members, 

including a Chair, designated by the 

Under Secretary in accordance with 

FACA requirements. Members will be 

appointed for three-year terms, 

renewable once, and serve at the 

discretion of the Under Secretary. If a 

member resigns before the end of his or 

her first term, the vacancy appointment 

shall be for the remainder of the 

unexpired term, and shall be renewable 

twice if the unexpired term is less than 

one year. Members will be appointed as 

special government employees (SGEs) 

and will be subject to the ethical 

standards applicable to SGEs. Members 

are reimbursed for actual and reasonable 

travel and per diem expenses incurred 

in performing such duties but will not 

be reimbursed for their time. As a 

Federal Advisory Committee, the 

Board’s membership is required to be 

balanced in terms of viewpoints 

represented and the functions to be 

performed as well as the interests of 

geographic regions of the country and 

the diverse sectors of U.S. society. 

The SAB meets in person three times 

each year, exclusive of teleconferences 

or subcommittee, task force, and 

working group meetings. Board 

members must be willing to serve as 

liaisons to SAB working groups and/or 

participate in periodic reviews of the 

NOAA Cooperative Institutes and 

overarching reviews of NOAA’s research 

enterprise. 

Nominations: Interested persons may 

nominate themselves or third parties. 

Applications: An application is 

required to be considered for Board 

membership, regardless of whether a 

person is nominated by a third party or 

self-nominated. The application package 

must include: (1) The nominee’s full 

name, title, institutional affiliation, and 

contact information; (2) the nominee’s 

area(s) of expertise; (3) a short 

description of his/her qualifications 

relative to the kinds of advice being 

solicited by NOAA in this Notice; and 

(4) a current resume (maximum length 

four [4] pages). 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 237 / Wednesday, December 10, 2014 / Notices 73279 

DATES: Nominations should be sent to 

the web address specified below and 

must be received by January 9, 2015. 

ADDRESSES: Applications should be 

submitted electronically to 

noaa.sab.newmembers@noaa.gov. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Cynthia Decker, Executive Director, 

Science Advisory Board, NOAA, Rm. 

11230, 1315 East-West Highway, Silver 

Spring, Maryland 20910. (Phone: 301– 

734–1156, Fax: 301–713–1459, Email: 

Cynthia.Decker@noaa.gov); or visit the 

NOAA SAB Web site at http://

www.sab.noaa.gov. 

SUPPLEMENTARY INFORMATION: 

Individuals are sought with expertise in 

meteorology, operational weather and 

water forecasting, water resources and 

climate. Individuals with expertise in 

the physical sciences, social sciences, 

and communications in these fields will 

all be given consideration. 

Dated: December 5, 2014. 

Jason Donaldson, 

Chief Financial Officer, Office of Oceanic and 

Atmospheric Research, National Oceanic and 

Atmospheric Administration. 

[FR Doc. 2014–28939 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–KD–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2014–0065] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,693,323; 

Recombinant Humanized Monoclonal 

Antibody (IgG1, Kappa)-Mepolizumab 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a one-year interim 

extension of the term of U.S. Patent No. 

5,693,323. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On November 24, 2014, 

GlaxoSmithKline LLC and SmithKline 

Beecham Limited timely filed an 

application under 35 U.S.C. 156(d)(5) 

for an interim extension of the term of 

U.S. Patent No. 5,693,323. The patent 

claims the human biological product 

Mepolizumab, a recombinant 

humanized monoclonal antibody (IgG1, 

Kappa). The application indicates that a 

Biologics License Application, BLA 

125526, for the human biological 

product has been filed, and is currently 

undergoing regulatory review before the 

Food and Drug Administration for 

permission to market or use the product 

commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because it is 

apparent that the regulatory review 

period will continue beyond the original 

expiration date of the patent, December 

23, 2014, interim extension of the patent 

term under 35 U.S.C. 156(d)(5) is 

appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,693,323 is granted for a period of one 

year from the original expiration date of 

the patent. 

Dated: December 5, 2014. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy, United States Patent and Trademark 

Office. 

[FR Doc. 2014–28966 Filed 12–9–14; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

Patent and Trademark Office 

[Docket No. PTO–P–2014–0067] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,496,801; 

Recombinant Human Parathyroid 

Hormone 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a second one-year 

interim extension of the term of U.S. 

Patent No. 5,496,801. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On October 29, 2014, NPS 

Pharmaceuticals, Inc., timely filed an 

application under 35 U.S.C. 156(d)(5) 

for a second interim extension of the 

term of U.S. Patent No. 5,496,801. The 

patent claims the human biological 

product recombinant human 

parathyroid hormone. The application 

indicates that Biologics License 

Application 125511 for the drug 

product, recombinant human 

parathyroid hormone, was filed on 

October 24, 2013, and is currently 

undergoing regulatory review before the 

Food and Drug Administration for 

permission to market or use the product 

commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because the 

regulatory review period will continue 

beyond the extended expiration date of 

the patent, December 23, 2014, interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,496,801 is granted for a period of one 

year from the extended expiration date 

of the patent. 

mstockstill on DSK4VPTVN1PROD with NOTICES